Kristine Ashcraft, Founder and President of YouScript, an Aranscia company, recently co-authored a research paper titled, “Comparison of targeted vs. expanded pharmacogenomic testing: What are we missing?.”
Per the paper, “Targeted testing did not identify up to 95% of total PGx gene-drug interactions discovered,” meaning that “targeted PGx testing for limited genes or by specialty may miss or not report significant portions of PGx gene-drug interactions.”
To read the full paper in PubMed, click here: https://pubmed.ncbi.nlm.nih.gov/37024375/
Disclaimer: AccessDx Laboratory and YouScript are both Aranscia companies.
